Journals / Journal of the Turkish-German Gynecological Association / 2019 / Cilt: 20 - Sayı: 4

The mammalian target of rapamycin protein expression in human granulosa cell tumors

Pages
247–254
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Rapamycin caused a dose-dependent growth arrest and apoptosis in COV434 mitotic granulosa cells.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To investigate the role of mammalian target of rapamycin (mTOR) in human granulosa cell ovarian tumors and the therapeutic effectof rapamycin in COV434 mitotic granulosa cell lines.Material and Methods: A retrospective evaluation of the medical records and pathologic sections of patients with granulosa cell ovariancarcinoma was performed. mTOR and p-mTOR expression was immunohistochemically investigated.
📊
Key Findings & Data:A COV434 cell culture were treated with0.5, 1, 2, and 5 μM rapamycin.
💡
Conclusion & Impact:Rapamycin caused a dose-dependent growth arrest and apoptosis in COV434 mitotic granulosa cells.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To investigate the role of mammalian target of rapamycin (mTOR) in human granulosa cell ovarian tumors and the therapeutic effectof rapamycin in COV434 mitotic granulosa cell lines.Material and Methods: A retrospective evaluation of the medical records and pathologic sections of patients with granulosa cell ovariancarcinoma was performed. mTOR and p-mTOR expression was immunohistochemically investigated. A COV434 cell culture were treated with0.5, 1, 2, and 5 μM rapamycin. Real-time growth curve analysis via xCELLigence system and apoptotic cell analysis via YO-PRO™-1 Iodide wereperformed to assess the therapeutic effect of rapamycin on cancer cells.Results: A total of twenty patients were evaluated. mTOR staining was detected in 18 (90%) patients. Mild, moderate, intense, and very intensestaining was observed in three (15%), eight (40%), six (30%), and one (5%) sample, respectively. The mean mTOR staining ratio was 59±41%.P-mTOR staining was observed in two (10%) patients. One (5%) patient had 5% staining, and one (5%) patient had 100% staining for p-mTOR.Both of the latter patients had very intense staining. Rapamycin caused a dose-dependent growth arrest and induced apoptosis in COV434 mitoticgranulosa cells. The real-time growth curves of the cells treated with these drugs were distinguished by a marked reduced slope after exposurefor several hours, indicating a rapid onset of apoptosis. Live/dead cell analysis with YO-PRO-1 staining showed that rapamycin induced apoptosisin 24% of the cells when used at 1 μM concentration, whereas the rate increased to 61% and 72% when the cells were treated with 2 μM and 5μM rapamycin, respectively.Conclusion: mTOR expression is observed in various degrees in 90%, and p-mTOR expression is observed in only 10% of patients with granulosacell ovarian carcinoma. Rapamycin caused a dose-dependent growth arrest and apoptosis in COV434 mitotic granulosa cells.

🔖

Cite This Article

GÜRALP, O., BESE, T., BİLDİK, G., DEMİKIRAN, F., İNCE, Ü., MALIK, E., ARVAS, M., ÖKTEM, Ö. (2022). The mammalian target of rapamycin protein expression in human granulosa cell tumors. Journal of the Turkish-German Gynecological Association, Cilt: 20 - Sayı: 4, 247–254. https://ajindex.com/articles/567472

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Jamieson S, Fuller PJ. Molecular pathogenesis of granulosa cell tumors of the ovary. Endocr Rev 2012; 33: 109-44
  2. Diaz-Padilla I, Duran I, Clarke BA, Oza AM. Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer. Cancer Treat Rev 2012; 38: 767-75
  3. Stuart GC, Dawson LM. Update on granulosa cell tumours of ovary. Curr Opin Obstet Gynecol 2003; 15: 33-7
  4. Yaba A, Bianchi V, Borini A, Johnson J. A putative mitotic checkpoint dependent on mTOR function controls cell proliferation and survival in ovarian granulosa cells. Reprod Sci 2008; 15: 128-38
  5. Yu J, Yaba A, Kasiman C, Thomson T, Johnson J. mTOR controls ovarian follicle growth by regulating granulosa cell proliferation. PLoS One 2011; 6: e21415
  6. Rico C, Laguë MN, Lefèvre P, Tsoi M, Dodelet-Devillers A, Kumar V, et al. Pharmacological targeting of mammalian target of rapamycin inhibits ovarian granulosa cell tumor growth. Carcinogenesis 2012; 33: 2283-92
  7. Garrett AP, Lee KR, Colitti CR, Muto MG, Berkowitz RS, Mok SC. K-ras mutation may be an early event in mucinous ovarian tumorigenesis. Int J Gynecol Pathol 2001; 20: 244-51
  8. Mok SC, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, Muto MG. et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993; 53: 1489-92
  9. Tajima K, Hosokawa K, Yoshida Y, Dantes A, Sasson R, Kotsuji F. et al. Establishment of FSH-responsive cell lines by transfection of pre-ovulatory human granulosa cells with mutated p53 (p53val135) and Ha-ras genes. Mol Hum Reprod 2002; 8: 48-57
  10. Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004; 23: 5853-7
  11. Mazzoletti M, Broggini M. PI3K/AKT/mTOR inhibitors in ovarian cancer. Curr Med Chem 2010; 17: 4433-47.